cyclic weak innov track
reduc forecast ebit due weaker-than-expect
perform reduc target price
maintain outperform rate organ growth margin continu
neg impact cyclic issu middl east disrupt weather
north america demand china disrupt continu longer
expect market increasingli concern around structur
problem busi remain outperform stock given
underli strength innov pipelin hygiene/corn led
manag confid return growth expect detail
short-term trade difficulti innov pipelin capit
market day june
still wait return growth continu forecast return
mid-singl digit structur growth post organ
leav longer term estim unchang support hygien
energy/household believ commod price support
growth growth new product pipelin
believ market gain comfort improv
remaind share outperform european
inocul uptak share gain
valuat new novozym target price dkr dkr
round averag pe multipl ev/ebitda
dcf reduct target price function
earn forecast reduct risk outperform thesi lower oil
soft commod price
valuat metric
number share
price month
price rel chart measur perform
omxc close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
novozym a/ denmark-bas biotechnolog compani
engag product sale industri enzym
busi consist two segment enzym busi segment
price jun rate outperform target price analyst mathew hampshire-waugh
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
return peak oil would gener organ growth
could justifi novozym rerat toward histor pe premium
return trough oil would gener organ growth could
justifi novozym derat toward low end histor pe
trade
price rel chart measur perform omxc
close
spot exchang rate
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
forecast organ growth vs novozym new guidanc
rang forecast underli ebit margin exclud defer
incom payment bioag deal previous chang longer term
forecast remain broadli unchang chang includ
revenu reduc forecast organ growth includ currenc
tailwind organ growth remain unchang household
novozym still guid low singl digit growth ag feed novozym
guid low singl digit decline-flat chang led
food beverag organ growth reduct led softer middl eastern
market fall demand grain china
bioenergi led sever weather us reduc plant season
ebit reduc margin reflect fall organ growth make chang
assum raw materi cost deal payment monsanto cse dkk
forecast organ ebit declin total forecast ebit growth due
follow addit non-organ item
currenc benefit due stronger usd vs dkk
defer revenu recognit addit earn contribut
defer revenu recognit bioag allianc chang dkr
receiv dkr less mn receiv last year
price dkr repres averag dcf ev/ebitda multipl
price-to-earnings multipl valuat methodolog seen
ev/ebitda multipl valuat price-to-earnings multipl valuat seen peer
figur ev/ebitda multipl price-to-earnings multipl valuat
dcf valuat seen
less increase/add decreas wc
free cash-flow firm fcff
cumul factor period
discount factor start first forecast period
equiti
debt
averag spread risk-fre rate
pre-tax cost debt
averag corpor tax rate compani
post-tax cost debt
number year explicit estim
year start termin period
highlight month forward consensu ev/ebitda novozym trade
discount peer discount year histor averag month
forward consensu price-to-earnings novozym trade discount peer
discount year histor averag
rel
compani mention price
